filmov
tv
Case 3: IDH Inhibitors for the Treatment of AML
Показать описание
Implications for treating relapsed/refractory IDH2-mutated acute myeloid leukemia with enasidenib based on supporting data.
Targeted Oncology
targeted oncology
oncology
cancer
Рекомендации по теме
0:05:29
Case 3: IDH Inhibitors for the Treatment of AML
0:06:25
Case 3: Targeting IDH in AML
0:07:06
Case 3: IDH2-Mutated AML
0:01:19
The next steps for the IDH2 inhibitor drug enasidenib
0:02:08
The impact of IDH mutations on the outcomes of patients with AML & inhibitors under investigatio...
0:05:47
IDH1/2 Inhibitors for AML
0:37:51
Implications of Rapid IDH1/IDH2 Testing for Liquid and Solid Tumors
0:08:31
Case 1: Allelic Burden in FLT3+ AML
1:24:06
Molecular Pathology: Kurt's Notes
0:00:45
Unlocking IDH1 IDH2 Mutations A Prognostic Key!
0:52:20
Acute Myeloid Leukemia: Incorporating Novel Treatment Approaches into Clinical Pathways
0:01:33
IDH Inhibition in Acute Myeloid Leukemia –Emergence of a New Therapeutic Era
0:03:56
IDH Inhibitor Ivosidenib Improve Overall Survival in Previously Treated Cholangiocarcinoma: ClarIDHy
0:06:35
IDH1/2 Inhibitors in AML
0:02:51
AML: mutant IDH1 inhibitor HMS-101
0:01:27
How do targeted treatments for IDH1 and IDH2 mutations work in acute myeloid leukemia (AML)?
0:02:28
Case 3: Moderate Chronic Graft-Versus-Host Disease
0:02:15
Case Presentation: IDH2-Mutated AML
0:02:08
Doctor Explains Glioma Brain Tumor
0:18:11
Targeted Therapies (enasidenib, ivosidenib, APR-246)
0:02:06
Highlights on IDH1 and 2 inhibitors
0:43:50
Clinical Cases: MRD in Real-World Clinical Practice
0:01:02
How Do IDH Mutations Cause Tumors?
0:59:51
Pathology Insights on Innovation in AML
visit shbcf.ru
0:05:29
0:06:25
0:07:06
0:01:19
0:02:08
0:05:47
0:37:51
0:08:31
1:24:06
0:00:45
0:52:20
0:01:33
0:03:56
0:06:35
0:02:51
0:01:27
0:02:28
0:02:15
0:02:08
0:18:11
0:02:06
0:43:50
0:01:02
0:59:51